argenx presents Vyvgart data: Goldman lifts argenx stock target to EUR 982.00
Published on 10/05/2026 at 11:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
argenx (ISIN NL0010832176) presented new VYVGART data at the AANEM and MGFA scientific sessions announced on September 29, 2026, while Goldman Sachs raised its target from EUR 973.00 to EUR 982.00 and kept a Buy rating. The stock was trading at EUR 821.00 at Lang & Schwarz on October 5, 2026, up 0.56 percent from the prior close of EUR 816.40.
VYVGART data broaden the evidence
According to GlobeNewswire on September 29, 2026, argenx reported data covering myasthenia gravis, chronic inflammatory demyelinating polyneuropathy and earlier pipeline programs. A real-world analysis of more than 1,100 U.S. patients associated earlier VYVGART treatment with better symptom outcomes, lower steroid burden and fewer exacerbations.
The clearest numerical comparison concerns treatment timing. Patients who started VYVGART within one year of diagnosis recorded a mean MG-ADL reduction of 4.70 points during the first three months, versus 3.50 points among patients treated more than three years after diagnosis, according to the same September 29 company release.
Analyst target moves to EUR 982.00
FinanzNachrichten reported on September 25, 2026, that Goldman Sachs lifted its Argenx target from EUR 973.00 to EUR 982.00 and maintained its Buy rating. The new target is EUR 161.00 above the Lang & Schwarz price, but the currencies and venues differ from the U.S. dollar quotation used for the primary listing context, so no target-distance percentage is applied.
For the latest reported quarter, MarketBeat said Argenx reported USD 1.54 billion in revenue and USD 7.32 in earnings per share for the second quarter of 2026. Revenue exceeded the USD 1.45 billion consensus estimate, while earnings per share topped the USD 5.86 consensus estimate by USD 1.46.
Stock stays below the yearly high
Finance data placed the primary Nasdaq quotation at USD 919.21 on October 2, 2026, with a 52-week range of USD 661.85 to USD 1,072.75 and market capitalization of USD 57.2 billion. The Nasdaq figure is separate from the Lang & Schwarz euro quote and is not used to calculate its daily move.
The next reported operating milestone is the third-quarter results date of October 22, 2026. That date gives the clinical data a near-term financial checkpoint, while the September results package keeps attention on VYVGART adoption and the breadth of argenx's neuromuscular pipeline.
October 5 price holds above prior close
argenx stock was trading at EUR 821.00 at Lang & Schwarz on October 5, 2026 at 11:49 a.m. CEST, plus 0.56 percent versus the Lang & Schwarz prior close of EUR 816.40 on October 2, 2026. The primary listing context is Nasdaq in USD, while argenx is also listed on Euronext Brussels.
The further course of trading is shown by the continuously updated real-time quote of argenx stock.
argenx stock facts
- Company: argenx SE
- ISIN: NL0010832176
- Ticker: ARGX
- Primary exchange: Nasdaq and Euronext Brussels
- Price Lang & Schwarz (as of October 5, 2026, 11:49 a.m. CEST): EUR 821.00
- Change versus prior close: plus 0.56 percent
- Prior close Lang & Schwarz (October 2, 2026): EUR 816.40
- Market capitalization: USD 57.2 billion (as of October 2, 2026)
- Sector / Industry: Biotechnology
- Next earnings date: October 22, 2026
